Abstract
The authors aimed to study the impact of adherence to imatinib during initial 6 mo on the cytogenetic response in pediatric chronic myeloid leukemia - chronic phase (CML CP). The hospital records of pediatric CML patients (age ≤18 y) from 2009 through 2012, were analyzed retrospectively for the drug adherence and cytogenetic response (CyR) at 6 mo. Forty eight children were analyzed, with the median age of 13 y (range 5–18) and slight male preponderance (M:F- 1.18:1). Sokal scores were low, intermediate and high in 14 (29.3 %), 26 (54.1 %), 8 (16.6 %) children respectively. Only a little more than half of the children were adherent (58 %). At the end of 6 mo, complete cytogenetic response (CCyR) was achieved by 78.5 % of adherent children as compared to 5 % of non-adherent children. Majority (80 %) of the non-adherent children had only a partial cytogenetic response (PCyR). Therefore, it is concluded that most of the adherent children had optimal cytogenetic response at the end of 6 mo and majority of those in the non-adherent group did not attain it.
Abbreviations
- CML CP:
-
Chronic myeloid leukemia - chronic phase
- CHR:
-
Complete hematological response
- CyR:
-
Cytogenetic response
- PCyR:
-
Partial cytogenetic response
- CCyR:
-
Complete cytogenetic response
- MPR:
-
Medication possession rate
- MEMS:
-
Micro electronic monitoring system
References
Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–42.
Bazeos A, Khorashad J, Mahon F-X, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients; American Society of Hematology (ASH) 51st annual meeting: Abstract. New Orleans, LA; 2009.
Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014;132:298–306.
Baccarani M, Deininger MW, Rosti G, et al. European leukemia net recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–84.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.
Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–96.
Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117:3733–6.
Noens L, van Lierde MA, De Bock R, Verhoef G, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11.
Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86:471–4.
dos Reis SRC, de Souza Quixadá AT, Nunes ST, et al. Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Rev Bras Hematol Hemoter. 2013;35:174–9.
Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response ismajor determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–6.
Acknowledgments
Max foundation, Novartis Oncology Access for free supply of Imatinib Mesylate (Glivec) in India.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Contributions
All the authors collected the hospital records of CML children and analyzed their data. Prof. Lakshmi Srinivas Maddali, Head, Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, will act as guarantor for the paper.
Conflict of Interest
None.
Source of Funding
None.
Rights and permissions
About this article
Cite this article
Ganta, R.R., Nasaka, S. & Gundeti, S. Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase. Indian J Pediatr 83, 1009–1012 (2016). https://doi.org/10.1007/s12098-015-2007-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-015-2007-9